Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 4/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31358977 | 1.00 | GPR139 (0.38) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31359084 | 0.87 | FEN1 (0.46) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31359026 | 0.87 | FEN1 (0.46) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31160920 | 0.87 | FEN1 (0.46) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31160860 | 0.87 | FEN1 (0.46) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31358968 | 0.86 | GPR139 (0.39) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31160811 | 0.86 | GPR139 (0.39) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31160950 | 0.86 | GPR139 (0.39) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31359138 | 0.86 | GPR139 (0.39) | GPR139PGRFEN1KMT2AMEN1 | |
| SCHEMBL31161080 | 0.85 | GPR139 (0.46) | GPR139PGRKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | GPR139 4045/4885PGR 3333/4885FEN1 3928/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | GPR139 3566/4885PGR 1852/4885FEN1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.